Effects of oral Lactobacillus administration on antioxidant activities and CD4+CD25+forkhead box P3 (FoxP3)+ T cells in NZB/W F1 mice

British Journal of Nutrition

Volumn 118, Issue 5, 2017, Pages 333-342

  Tzang, Bor Show ^a,b   Liu, Chung Hsien ^a   Hsu, Kuo Ching ^a   Chen, Yi Hsing ^c,d   Huang, Chih Yang ^e,f   Hsu, Tsai Ching ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Research and Development Department   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

Author keywords

Comprehensive treatment; Lactobacillus paracasei GMNL 32; Lactobacillus reuteri GMNL 263; Lactobacillus reuteri GMNL 89; Systemic lupus erythematosus

Indexed keywords

INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; ANTIOXIDANT; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; GLUTATHIONE; IL2RA PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; THIOBARBITURIC ACID; THIOBARBITURIC ACID DERIVATIVE; TOLL LIKE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BACTERIAL STRAIN; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOREGULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LACTOBACILLUS PARACASEI; LACTOBACILLUS REUTERI; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPLEMENTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; BLOOD; CLASSIFICATION; CYTOLOGY; DISEASE MODEL; LACTOBACILLUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; NEW ZEALAND BLACK MOUSE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLUTATHIONE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-6; LACTOBACILLUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB; PROBIOTICS; RNA, MESSENGER; THIOBARBITURATES; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85029682432     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114517002112     Document Type: Article

References (52)

1. Gerritsen J, Smidt H, Rijkers GT, et al. (2011) Intestinal microbiota in human health and disease: The impact of probiotics. Genes Nutr 6, 209-240.
2. Wang G, Cai P, Ansari GA, et al. (2007) Oxidative and nitrosative stress in trichloroethenemediated autoimmune response. Toxicology 229, 186-193.
3. Wang G, Pierangeli SS, Papalardo E, et al. (2010) Markers of oxidative and nitrosative stress in systemic lupus erythematosus: Correlation with disease activity. Arthritis Rheum 62, 2064-2072.
4. Ozkan Y, Yardým-Akaydýn S, Sepici A, et al. (2007) Oxidative status in rheumatoid arthritis. Clin Rheumatol 26, 64-68.
5. Grimsrud PA, Xie H, Griffin TJ, et al. (2008) Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem 283, 21837-21841.
6. Frostegård J, Svenungsson E, Wu R, et al. (2005) Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52, 192-200.
7. Kurien BT, Scofield RH (2008) Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 7, 567-573.
8. Jacob N, Stohl W (2011) Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 13, 228.
9. Hahn BH (1993) An overview of the pathogenesis of systemic lupus erythematosus. In Dubois' Lupus Erythematosus, pp. 69-76 [DJ Wallace and BH Hahn, editors]. Philadelphia, PA: Williams and Wilkins.
10. Linker-Israeli M, Deans RJ, Wallace DJ, et al. (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147, 117-123.
11. Peterson E, Robertson AD, Emlen W (1996) Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 5, 571-575.
12. Schiffer L, Bethunaickan R, Ramanujam M, et al. (0082) Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 180, 1938-1947.
13. Cash H, Relle M, Menke J, et al. (2010) Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRLFaslpr mice: The IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol 37, 60-70.
14. Gröndal G, Gunnarsson I, Rönnelid J, et al. (2000) Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 18, 565-570.
15. Boswell JM, Yui MA, Burt DW, et al. (1988) Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 141, 3050-3054.
16. Yokoyama H, Kreft B, Kelley VR (1995) Biphasic increase in circulating and renal TNF-in MRL-lpr mice with diff ering regulatory mechanisms. Kidney Int 47, 122-130.
17. Studnicka-Benke A, Steiner G, Petera P, et al. (1996) Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35, 1067-1074.
18. Gabay C, Cakir N, Moral F, et al. (1997) Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are signifi cantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 24, 303-308.
19. Lescheid DW (2014) Probiotics as regulators of inflammation: A review. Funct Foods Health Dis 4, 299-311.
20. de Moreno de LeBlanc A, Matar C, Perdigon G (2007) The application of probiotics in cancer. Br J Nutr 98, Suppl. 1, S105-S110.
21. Laitinen K, Poussa T, Isolauri E (2009) Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: A randomised controlled trial. Br J Nutr 101, 1679-1687.
22. Thomas CM, Versalovic J (2010) Probiotics-host communication. Modulation of signaling pathways in the intestine. Gut Microbes 1, 148-163.
23. Bermudez-Brito M, Plaza-Diaz J, Munoz-Quezada S, et al. (2012) Probiotic mechanisms of action. Ann Nutr Metab 61, 160-174.
24. Di Giacinto CD, Marinaro M, Sanchez M, et al. (2005) Probiotics ameliorate recurrent Th-1 mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-bearing regulatory cells. J Immunol 174, 3237-3246.
25. Timmerman HM, Koning CJ, Mukder L, et al. (2004) Monostrain, multistrain and multispecies probiotics-a comparison of functionality and efficacy. Int J Food Microbiol 96, 219-233
26. Honad K, Littman DR (2012) The microbiome in infectious disease and inflammation. Ann Rev Immunol 30, 758-795.
27. Dwivedi M, Kumar P, Laddha NC, et al. (2016) Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity. Autoimmun Rev 15, 379-392.
28. Makarova K, Slesarev A, Wolf Y, et al. (2006) Comparative genomics of the lactic acid bacteria. Proc Natl Acad Sci USA 103, 15611-15616.
29. Goldstein EJ, Tyrrell KL, Citron DM (2015) Lactobacillus species: Taxonomic complexity and controversial susceptibilities. Clin Infect Dis 60, S98-S107.
30. Liao PH, Kuo WW, Hsieh DJ, et al. (2016) Heat-killed Lactobacillus reuteri GMNL-263 prevents epididymal fat accumulation and cardiac injury in high-calorie diet-fed rats. Int J Med Sci 13, 569-577.
31. Ting WJ, Kuo WW, Hsieh DJ, et al. (2015) Heat killed Lactobacillus reuteri GMNL-263 reduces fibrosis effects on the liver and heart in high fat diet-hamsters via TGF-suppression. Int J Mol Sci 16, 25881-25896.
32. Tian XP, Zhang X (2010) Gastrointestinal involvement in systemic lupus erythematosus: Insight into pathogenesis, diagnosis and treatment. World J Gastroenterol 16, 2971-2977.
33. Hsu TC, Huang CY, Liu CH, et al. (2017) Lactobacillus paracasei GMNL-32, Lactobacillus reuteri GMNL-89 and L. reuteri GMNL-263 ameliorate hepatic injuries in lupus-prone mice. Br J Nutr 117, 1066-1074.
34. Lin CH, Lin CC, Shibu MA, et al. (2014) Oral Lactobacillus reuteri GMN-32 treatment reduces blood glucose concentrations and promotes cardiac function in rats with streptozotocininduced diabetes mellitus. Br J Nutr 111, 598-605.
35. Hsu TC, Chiu CC, Wang YW, et al. (2013) Effects of cystamine on antioxidant activities and regulatory T cells in lupusprone mice. J Cell Mol Med 17, 1308-1315.
36. Isolauri E (2001) Probiotics in human disease. Am J Clin Nutr 73, 1142S-1146S.
37. Schiffer C, Lalanne AI, Cassard L, et al. (2011) A strain of Lactobacillus casei inhibits the effector phase of immune inflammation. J Immunol 187, 2646-2655.
38. Zamani B, Golkar HR, Farshbaf S, et al. (2016) Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial. Int J Rheum Dis 19, 869-879.
39. Morgan PE, Sturgess AD, Davies MJ (2005) Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 52, 2069-2079.
40. Shah D, Mahajan N, Sah S, et al. (2014) Oxidative stress and its biomarkers in systemic lupus erythematosus. J Biomed Sci 21, 23.
41. Perl A (2013) Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol 9, 674-686.
42. Wu YW, Tang W, Zuo JP (2015) Toll-like receptors: Potential targets for lupus treatment. Acta Pharmacol Sin 36, 1395-1407.
43. Celhar T, Magalhães R, Fairhurst AM (2012) TLR7 and TLR9 in SLE: When sensing self goes wrong. Immunol Res 53, 58-77.
44. Lyn-Cook BD, Xie C, Oates J, et al. (2014) Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: Ethnic differences and potential new targets for therapeutic drugs. Mol Immunol 61, 38-43.
45. Hsu TC, Chiang SY, Wu JH, et al. (2008) Treatment with taurine attenuates hepatic apoptosis in NZB/W F1 mice fed with a high-cholesterol diet. J Agric Food Chem 56, 9685-9691.
46. Hsu TC, Huang CY, Chiang SY, et al. (2008) Transglutaminase inhibitor cystamine alleviates the abnormality in liver from NZB/W F1 mice. Eur J Pharmacol 579, 382-389.
47. Tzang BS, Chiang SY, Lai WX, et al. (2008) Treatment with cystamine reduces apoptosis in liver from NZB/W F1 mice. Int Immunopharmacol 8, 589-596.
48. Hsu TC, Chen YC, Tsai CC, et al. (2010) Protective effects of taurine against hepatic abnormality in NZB/W F1 mice fed a hypercholesterolemic diet. Food Chem 119, 62-68.
49. Mathian A, Weinberg A, Gallegos M, et al. (2005) IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 174, 2499-2506.
50. Wang G, König R, Ansari GA, et al. (2008) Lipid peroxidationderived aldehyde-protein adducts contribute to trichloroethene mediated autoimmunity via activation of CD4T cells. Free Radic Biol Med 44, 1475-1482.
51. La Cava A (2008) T-regulatory cells in systemic lupus erythematosus. Lupus 17, 421-425.
52. Chen Y, Cuda C, Morel L (2005) Genetic determination of T cell help in loss of tolerance to nuclear antigens. J Immunol 174, 7692-7702.